insights_auto
Pse është rritur 688235 4,06%?
Zhytu më thellëchevron_right
688235:SHA
BeOne Medicines AG
255,98 CN¥
arrow_upward
+4,06%(+9,99) 1D
16 tet, 3:00:00 m.d., GMT+8 · CNY
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për 688235...
Hap
253,20 CN¥
I lartë
268,18 CN¥
I ulët
252,09 CN¥
Kapitalizimi i tregut
303,26 mld
Vëllimi mesatar
2,81 mln
Vëllimi
5,69 mln
Raporti çmim/fitim
91,43
Maksimumi 52-javor
319,24 CN¥
Minimumi 52-javor
205,51 CN¥
Fitimet për aksion
2,80 CN¥
Numri i punonjësve
12 mijë
Hap
253,20 CN¥
I lartë
268,18 CN¥
I ulët
252,09 CN¥
Kapitalizimi i tregut
303,26 mld
Vëllimi mesatar
2,81 mln
Vëllimi
5,69 mln
Raporti çmim/fitim
91,43
Maksimumi 52-javor
319,24 CN¥
Minimumi 52-javor
205,51 CN¥
Fitimet për aksion
2,80 CN¥
Numri i punonjësve
12 mijë
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
ad-hoc-news.de
·
19 orë më parë
Morgan Stanley lifts target for BeOne Medicines stock to USD 425.00
Profili
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Rreth BeOne Medicines AG
Drejtori ekzekutivJohn Vincent Oyler | John Vincent Oyler
Punonjësit12 mijë
Themeluar më28 tet 2010
Selia-
Sektori-
Uebsajtibeonemedicines.com